Home > Boards > US Listed > Biotechs > Cellectar Biosciences Inc. (CLRB)

7:44 am ET June 23, 2020

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 19
Posts 1,519
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 1/21/2021 5:23:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/12/2021 4:47:24 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 1/8/2021 4:32:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/28/2020 4:32:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/28/2020 4:32:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/28/2020 4:31:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/28/2020 4:16:55 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/23/2020 4:04:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/23/2020 10:35:16 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/23/2020 6:00:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2020 4:05:25 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2020 9:01:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2020 4:07:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2020 4:11:31 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/21/2020 6:02:58 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/17/2020 4:03:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/11/2020 4:27:10 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/11/2020 4:16:43 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 8:31:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 8:15:46 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 4:06:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/21/2020 4:03:14 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/13/2020 2:38:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2020 4:16:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/6/2020 6:32:07 AM
stockguard   Tuesday, 06/23/20 02:29:46 PM
Re: None
Post # of 8038 
7:44 am ET June 23, 2020
Cellectar Biosciences started at buy with $3 stock price target at Maxim Group

Maxim analyst Jason McCarthy initiated coverage of Cellectar Biosciences with a Buy rating and $3 price target. The analyst says the data in the company's development of phospholipid drug conjugates to target cancer's "addiction" to phospholipids have been "compelling". McCarthy further notes additional catalysts expected in the second half of 2020 and in 2021, with "updates on a pediatric study in solid tumors and r/r blood cancers", adding that Cellectar should also have cash runway well into 2021



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences